Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fevipiprant - Novartis

Drug Profile

Fevipiprant - Novartis

Alternative Names: NVP-QAW-039; QAW-039; QAW-39A; QAW39-A2107

Latest Information Update: 05 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Acetic acids; Anti-inflammatories; Antiallergics; Antiasthmatics; Pyridines; Pyrroles; Skin disorder therapies
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Nasal polyps
  • Phase II Atopic dermatitis; Chronic obstructive pulmonary disease
  • No development reported Allergic rhinitis
  • Discontinued Allergic asthma; Asthma

Most Recent Events

  • 19 Jan 2020 Novartis terminates a phase II trial in Asthma (In children) in Spain (PO) (EudraCT2018-003920-35)
  • 31 Dec 2019 Discontinued - Phase-II for Allergic asthma in Bulgaria, Colombia, France, Greece, Guatemala, India, Italy, Japan, Mexico, Peru, Poland, Russia, South Africa, Turkey, Czech Republic, United Kingdom, Argentina, South Korea and Romania (PO)
  • 31 Dec 2019 Discontinued - Phase-III for Allergic asthma (In adolescents, In the elderly, In adults) in Vietnam, Switzerland, Singapore, Romania, Poland, Philippines, Luxembourg, Lithuania, Ireland, Greece, Guatemala, France, Finland, Denmark, China, Australia, Argentina, United Kingdom, Spain, Latvia, Iceland, Hungary, Belgium, Germany, Estonia, Austria and USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top